The latest price target for Citius Pharmaceuticals (NASDAQ:CTXR) was reported by D. Boral Capital on March 11, 2026. The analyst firm set a price target for $6.00 expecting CTXR to rise to within 12 months (a possible 603.81% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Citius Pharmaceuticals (NASDAQ:CTXR) was provided by D. Boral Capital, and Citius Pharmaceuticals maintained their buy rating.

The last upgrade for Citius Pharmaceuticals Inc happened on December 30, 2024 when D. Boral Capital raised their price target to $9. D. Boral Capital previously had a hold for Citius Pharmaceuticals Inc.

The last downgrade for Citius Pharmaceuticals Inc happened on May 23, 2025 when Maxim Group changed their price target from N/A to N/A for Citius Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Citius Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Citius Pharmaceuticals was filed on March 11, 2026 so you should expect the next rating to be made available sometime around March 11, 2027.

While ratings are subjective and will change, the latest Citius Pharmaceuticals (CTXR) rating was a maintained with a price target of $6.00 to $6.00. The current price Citius Pharmaceuticals (CTXR) is trading at is $0.85, which is out of the analyst’s predicted range.